ArticleThe Eurasian journal of medicine2023
Brain-Derived Neurotrophic Factor Levels in Mesenchymal Stem Cell Culture Fluid Under Different Culture Conditions.
Article in The Eurasian journal of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 citations in OpenAlex.
- Stem Cell Therapy: Past, Present, and Future Aspects.Biomedicines · 2026Review
- The Role and Mechanism of Hair Follicle Neural Crest Stem Cells and Their Small Extracellular Vesicles in Repair of Peripheral Nerve Injury.Stem cells international · 2026Review
- From laboratory to clinic: a precise treatment strategy of mesenchymal stem cells-derived exosomes pretreated by simulating disease microenvironment.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMesenchymal stem cells are used in various fields, such as cellular therapy, regeneration, or tissue engineering. It has been shown that they exhibit many protective factors and also work as a modulating chief within the region in which they are administered. There are studies on both the therapeutic and neuroprotective effects of brain-derived neurotrophic factor. Also, there are many studies on the improvement of culture conditions for in vitro reproduction of mesenchymal stem cells, which can be obtained from many sources in various bodies, such as adipose tissue and Wharton's jelly. Improving and standardizing these culture conditions will increase the effectiveness and reliability of stem cell therapies. Studies evaluating many culture conditions, such as O2 level, type of medium, monolayer culture, and the transition from in vitro 3D models, are ongoing. MATERIALS AND
methodsIn our study, groups were formed by using stem cells originating from adipose tissue and Wharton's jelly. Stem cell cultures were made using Hillex-II and Pronectin-F microcarriers. Cell culture O2 level was adjusted as 1% and 5% for each group separately. Enzyme-linked immunosorbent assay was used to analyze brain-derived neurotrophic factor levels in stem cell culture fluid.
resultsThe highest brain-derived neurotrophic factor level in mesenchymal stem cells culture medium was observed in an adipose-derived stem cell culture with an in vitro fertilization (non-treated) dish, using a Hillex microcarrier in a 1% O2 microenvironment.
conclusionAs a result of our observations, we think that cells could exhibit greater therapeutic potential in a dynamic adhesion environment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.